In our cohort, the INSIG1 promoter SNP rs2721 was associated with TG levels (p=2 x 10 -3 in 1,560 individuals of the original linkage cohort, p=8 x 10 -4 in 920 unrelated individuals of the replication cohort, combined p=9.9 x 10 -6 ). Individuals homozygous for the T allele had 9% higher TG levels, and two-fold lower expression of INSIG1 in surgical liver biopsy samples when compared to individuals homozygous for the G allele.
Introduction
Increased plasma triglyceride (TG) levels are an important cardiovascular risk factor, and are strongly associated with atherosclerotic heart disease (1,2). Plasma TG levels vary widely between individuals, and both genetic and environmental factors have been shown to contribute to elevated plasma TG concentrations (3) (4) (5) (6) (7) . Elevated plasma TG levels are often observed in obese and diabetic individuals and in individuals affected by the metabolic syndrome, a common chronic disorder associated with obesity, insulin resistance, hypertension, and alterations in plasma lipid profile such as elevated serum triglycerides and low HDL levels. This characteristic pattern is similar to lipid abnormalities reported in familial combined hyperlipidemia (8) .
The Metabolic Risk Complications of Obesity Genes (MRC-OB) project was established in 1994 to identify the genetic determinants of the metabolic syndrome and its metabolic abnormalities (9) . As part of the project, 2,209 individuals from 507 families were ascertained for basic anthropomorphic phenotypes, plasma lipid measures, and fasting glucose and insulin levels. A genome-wide linkage scan of these families identified a quantitative trait locus (QTL) on human chromosome 7q36 linked to plasma triglyceride levels (LOD=3.7) (10) . This region has also been implicated in numerous other studies (11) (12) (13) (14) (15) , and represents one of the most replicated linkages for dyslipidemia and elevated TG levels. The genomic interval on chromosome 7q36 includes 22 known genes, including insulin-induced gene 1 (INSIG1), the only biological candidate.
INSIG1 was initially described as an insulin-induced transcript, designated CL-6 (16) . It was later re-named INSIG1 following cloning and assignment to chromosome 7q36 (17) . INSIG1 has been shown to affect the feedback regulation of cellular cholesterol (18, 19) . Sterol regulatory element binding proteins (SREBPs), which are transcription factors located in the endoplasmic reticulum, control the synthesis of cholesterol and fatty acids. When cellular cholesterol levels fall, SREBPs bind to SREBP cleavage-activating proteins (SCAPs) in order to be transported to the Golgi, where they undergo proteolytic cleavage (20) . The NH 2 -terminal fragment translocates to the nucleus to activate the transcription of target genes including INSIG1 (21) that are involved in the synthesis of cholesterol and fatty acids. As cellular sterol levels rise, SCAP binds to INSIG1, thus preventing the transport of the SCAP/SREBP complex to the Golgi (18) and halting the synthesis of cholesterol and fatty acids (for detailed reviews, see (22, 23) ).
INSIG1 and its only mammalian homologue INSIG2 may also exert their feedback regulators of cholesterol synthesis by directly binding to 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which triggers sterol-accelerated ubiquitination and degradation of HMG CoA reductase, the rate-limiting enzyme of cholesterologenesis (for a detailed review, see (24) ).
Over-expression of INSIG1 has been shown to reduce high levels of TG in both liver and plasma of Zucker diabetic fatty rats (25) . It has been proposed that this effect is due to the mechanism outlined above (18) . In addition, single knockout of either INSIG1 INSIG2 in mice leads to increased total content of both cholesterol and TG in mouse livers, an effect exacerbated significantly when both INSIG genes are knocked out (26 
Methods

Study Design
We performed a family-based study on genetic contributions to plasma triglyceride levels.
Study cohort
Cohort recruitment and individual phenotyping have been described in detail previously (9, 10) . In brief, families with at least two obese siblings [body mass index (BMI) >30], the availability of at least one parent, and one or more never obese siblings (BMI <27)
were recruited from the TOPS (Take Off Pounds Sensibly, Inc.) membership in ten Midwestern U.S. states. Health information of all participants was obtained by a questionnaire. Individuals were excluded from recruitment with the following conditions: pregnancy, type 1 diabetes, history of cancer, renal or hepatic disease, severe coronary artery disease, substance abuse, corticosteroids or thyroid dosages above replacement dose, history of weight loss of more than 10% in the preceding 12 months, as well as individuals receiving lipid-lowering medications. Phenotypic measurements included height, weight, waist and hip circumferences, and fasting plasma levels of glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, and TG. A total of 2,209 individuals distributed over 507 families of Northern European descent qualified for the above-mentioned criteria and thus formed the initial study population, of which 1,560 individuals from 261 families that contributed to the linkage on chromosome 7q36 (family LOD >0) were selected for further studies reported here.
Confirmatory studies were performed from a cohort of unrelated individuals of Northern European descent recruited by the same criteria from the same geographic regions. Samples from 920 unrelated individuals were available for this study. All protocols were approved by the Institutional Review Board of the Medical College of Wisconsin, and all participants signed an informed consent. Details on the two cohorts used in this study are included in Table 1 .
Measurements
Genotyping
SNPs were genotyped using Invader technology as described for previous studies (27) (28) (29) (30) . Genotyping was carried out in a total volume of 6µl, containing 0.5µl of PCR product, 0.02µl of each primary probe, 0.002µl of Invader probe, 1.12µl of 2.6M betaine (Sigma, St.Louis, MO), 2.75µl TE buffer, 0.35µl Cleavase (TWT) and 1.24µl FRET mix (TWT). Reactions were denatured at 95°C for five minutes and then heated at 63°C for 15-120 min. Additional SNPs were genotyped on an Affymetrix MegAllele customdesigned 3K array using molecular inversion probe technology, as described previously (28) . The location of all SNPs included in the analysis is shown in Figure 1 .
Sequencing and SNP identification
A 4,139 bp region was re-sequenced in 47 unrelated individuals selected from the MRC-OB cohort. The region was amplified by PCR using 21 overlapping amplicons 261 to 444 bp in size. PCR products were purified using MultiScreen-FB plates (Millipore); and eluted in sterile H 2 O for sequencing. Sequencing was carried out using BigDye v.3.1 chemistry (Applied Biosystems, CA, USA) with standard techniques and analyzed on an Applied Biosystems 3730xl DNA Analyzer. SNP loci were identified by aligning all sequences using POLYPHRED (31) , all putative sites were checked manually for confirmation. Results were independently confirmed by aligning all traces with the chromosome 7 reference sequence using the anchored alignment algorithm in POLYBAYES (32) and using POLYPHRED to screen for SNPs.
Expression profiling
RNA isolation, anti-sense RNA generation and Illumina BeadChip hybridization of the liver samples as well as transcript detection and normalization were performed as previously described (33) . Briefly, a liver biopsy was obtained from each of 73 morbidly obese subjects of Northern European descent undergoing bariatric surgery. RNA was extracted and analyzed using Illumina Human-6 Expression BeadChips which allow interrogation of almost 48,000 transcripts. Gene expression data for all liver samples were analyzed according to Goring et al. (33) . To identify transcripts with detectable quantitative expression in the samples, distribution of expression values for a given transcript were compared to those of the controls imbedded in each chip. All significantly expressed transcripts were identified using an FDR of 0.05. To minimize the influence of overall signal levels, which may reflect RNA quantity and quality rather than a true biological difference between individuals, abundance values of all transcripts were standardized by z-scoring within individuals (using decile percentage bins of transcripts, grouped by average log transformed raw signals across individuals), followed by linear by guest, on November 3, 2010 www.jlr.org Downloaded from regression against the individual-specific average log-transformed raw signal and its squared value, as discussed by Goring et al. (33) .
For the analysis of allele-specific expression differences in INSIG1, individuals were grouped according to genotype (for rs2721), and their gene-specific normalized expression z-scores were compared for genotype-specific differences using ANOVA.
Differences between individual genotypes were compared using t-tests.
Electrophoretic Mobility Shift Assay (EMSA)
The human HepG2 cell line was maintained in DMEM, supplemented with 2 mM Lglutamine, 100 mg/ml each of streptomycin and penicillin, and 15% fetal bovine serum, at 37°C with 5% CO 2. Complementary oligonucleotides representing both allelic forms of the INSIG1 promoter SNP (rs2721, G>T at -2253 to the start codon) were obtained commercially (Integrated DNA Technologies) and purified by high performance liquid chromatography (HPLC). EMSA was performed as described previously (34) . Briefly, 
Statistical Analysis
Initial association analysis discovered rs2721
As triglyceride levels are continuously distributed, the data were first examined for deviations from normality. Raw triglyceride levels exhibited an increased number of high values, so the data were natural log (ln) transformed. Data were re-examined and observations exceeding 4 standard deviation units were removed as outliers. In all models, triglycerides were adjusted for age, sex, age by sex, age squared, age squared by sex, and type 2 diabetes status.
To test for statistical association with SNPs in INSIG1, we identified 11 tagSNPs in the INSIG1 gene region (~40 kb) from the Hapmap database using the tagger function in Haploview with default settings (35, 36) . After sequencing the promoter and the first exon of INSIG1 in 47 unrelated individuals, we identified an additional 17 SNPs. All 28
SNPs were genotyped in the full cohort (n = 1560) and were tested for association with
ln(triglycerides).
For each SNP, we used the measured genotype approach to test for association.
Briefly, in this approach the effects of the individual SNP genotypes will be modeled by
assigning genotypic values such that the homozygotes will be assigned values of 1 and -1 and the heterozygotes will be assigned 0, providing an additive model (37) . To account for the phenotypic correlation between family members, we used variance components analysis with the SNPs screened individually as covariates in the computer program SOLAR (Sequential Oligogenic Linkage Analysis Routines) (38) .
Confirmatory association analysis in unrelated individuals
To confirm associations identified in the family-based analyses, we genotyped SNP rs2721 in a cohort of 920 unrelated individuals. Genotypes were coded as described above and were considered the independent variable. Triglycerides were ln transformed to improve normality of the distribution. As this was an unrelated cohort, we performed linear regression analysis using SAS v9.1 (SAS, Carey NC).
Meta-Analysis of both cohorts
To assess the combined effect of rs2721 in both cohorts, we combined the p-values using the Z-transformation. This approach is detailed by Whitlock et al. (39) and implemented in the Util program (http://www.genemapping.cn/util.htm).
Interaction analysis with INSIG2
To determine whether there was an interaction between INSIG1 and INSIG2, as suggested from mouse knockout studies, we first examined the relationship between the family specific LOD scores for triglycerides at the two loci (40 
Results
Association of INSIG1 sequence variants with TG in the MRC-OB cohort
The QTL on chromosome 7q35-q36 linked to plasma TG levels has been replicated in multiple cohorts (10) (11) (12) (13) (14) (15) . Among the 22 identified genes in this QTL, INSIG1 is the only candidate with known biological roles that are related to lipid metabolism and therefore has been the focus of this study.
Initially, we tested for INSIG1 association using 11 SNPs selected from the Hapmap database using the tagger function of Haploview (35, 36) ( Figure 1 and Table 2 ).
These SNPs spanned the entire INSIG1 gene region (39.7 kb). One variant in the putative promoter region of INSIG1, rs2721, was significantly associated with plasma triglyceride levels in 1,560 individuals from our cohort (p=0.002). Two additional SNPs (rs9770068 and rs9769506) located in intron 6 of INSIG1, showed marginal association (p=0.047 and p=0.037, respectively), as well as one additional SNP in the promoter region (rs9690040, p=0.045). As these three marginally associated SNPs are in almost complete linkage disequilibrium with rs2721 ( Fig.1) , we speculate that their high degree of correlation may have led to the observed associations.
The promoter variant (rs2721) is located 2253 bp upstream of the transcription start site of INSIG1. In order to include all other variants surrounding rs2721 in the association analysis, we re-sequenced the promoter region and exon 1 in 47 unrelated individuals from our cohort. SNPs in the remaining exons of the gene were in high LD with each other, and not in LD with rs2721, thus, we focused solely on the region surrounding rs2721. All selected individuals were parents from families contributing significantly to the initially observed linkage on chromosome7 in the MRC-OB cohort.
The re-sequencing effort uncovered 17 additional SNPs, of which 8 were novel and not reported in dbSNP. The location of all SNPs is shown in Figure 1 .
All 28 SNPs were genotyped in the 1,560 individuals from the MRC-OB cohort.
The results of the association analysis are summarized in Table 2 . No additional SNPs were associated with plasma triglyceride levels in this cohort, suggesting that the effect is primarily mediated by rs2721. The TG levels of individuals homozygous for the G allele (123.1±2.3 mg/dl, n=1073) were on average 9% lower than those of individuals homozygous for the T allele (135.9±16.2 mg/dl, n=31).
Next, we examined the effect of the SNP on the initial linkage. Overall, the QTL interval on chromosome 7q36 explains 31% of the variance in TG levels in our cohort.
When including SNP rs2721 in INSIG1 as a covariate, the linkage drops 5.4% for our family-based cohort, suggesting a modest but significant effect on the initial linkage on chromosome 7q36 that explains 1.6% of the total observed variance in TG levels in the study cohort.
Replication of association analysis
To validate the association seen in the family-based MRC-OB cohort, we examined the effect of the associated variant rs2721 in a second study cohort. The details of the cohort are summarized in Table 1 . 920 individuals were genotyped and included in the analysis.
The minor allele frequency (MAF) of rs2721 in this cohort is comparable to the MAF of rs2721 in the initial family-based cohort (15.1% vs. 14.5%). Again, rs2721 is strongly associated with plasma triglyceride levels (p=8×10 -4 ), confirming the finding in our initial family-based cohort. In this replication cohort, individuals homozygous for the T allele of rs2721 (n=21) had mean TG levels of 150.3±18.8 mg/dl, compared to 135.9±2.9 mg/dl for individuals homozygous for the G allele (n=674).
When both datasets are combined using a Z-transformation (39), rs2721 is associated with altered TG levels with a p-value of 9.9 x 10 -6 .
Functional analysis of rs2721
To assess whether rs2721 may have a direct functional effect, we examined whether the 
Interaction between INSIG1 and INSIG2
In humans, the INSIG1 protein is 78% similar to its only homologue INSIG2.
Interestingly, while INSIG1 is involved in the feedback regulation of lipid synthesis,
INSIG2 has been shown to be associated with obesity and adipocyte metabolism in a number of recent studies (41) (42) (43) . However, no study to date has addressed whether these two genes work cooperatively in humans to affect lipid levels, as has been shown in mice (26) . and LDL-C in other studies (41) (42) (43) . Gene-gene interaction analysis was performed on the two INSIG2 SNPs and rs2721 of INSIG1. In this analysis, SNP rs2422166 did not show any effect on TG levels directly or through interaction with rs2721. In contrast, SNP rs7566605 showed marginal interaction with rs2721 (p=0.0473) although it was not directly associated with TG levels. To measure the impact of genotype at rs7566605 on the association of rs2721 with lipid traits, we grouped the data based on genotype at rs7566605. Measured genotype analysis was then performed in these subsets (Table 3 ). In the GG subgroup, the associations with TG levels disappeared. In contrast, in the CC-CG subgroup, the association was significantly strengthened (β=0.13±0.04, p=0.00117).
Here, individuals homozygous for the T allele of rs2721 had 31% higher TG levels than individuals homozygous for the G allele (138.4±1.9 mg/dl vs. 105.6±1.7 mg/dl). Before we stratified the study cohort based on genotypes of INSIG2 rs7566605, the difference between the INSIG1 rs2721 homozygous groups was only 8%.
Discussion
Studies conducted in animals have revealed intriguing and critical roles of INSIG genes in lipid homeostasis (26) . By anchoring a sterol-sensing retainer protein that is able to block the access to the nucleus of a number of transcription factors, INSIG proteins have been recognized as key regulators of both cholesterol and fatty acid synthesis (18, 19, 21) . No study, however, has shown evidence of their proposed roles in lipid homeostasis in humans. Based on the fact that the gene for INSIG1 is located in a QTL region linked to plasma TG levels in our MRC-OB cohort, we examined the role of sequence variants in the gene in the modulation of plasma TG levels.
Our initial association analysis using eleven tagSNPs revealed four SNPs associated with TG levels. Further analysis of additional sequence variants uncovered by re-sequencing suggested the promoter SNP rs2721 as the likely causal variant for the observed hyperlipidemia. Genotype effect assessment showed that people homozygous for the T allele at rs2721 had significantly elevated plasma TG levels. The association was replicated in a second independent cohort, detecting a similar effect in individuals homozygous for the T allele. These data suggest that rs2721 in INSIG1 may be causally associated with TG levels in our linkage region. However, our analysis also suggests that this variant accounts for only a portion of the overall linkage (~5%), suggesting that other variants and genes in the QTL interval also affect plasma TG levels. Overall, variance at rs2721 explains 1.6% of the observed variance in TG levels in our family cohort. This To further validate this potential effect of SNP rs2721 on the promoter function of INSIG1, we examined the binding of nuclear proteins to the sequence surrounding rs2721
by electrophoretic mobility shift assay. Separate custom oligonucleotides specific for the alleles of rs2721 and comprising the immediate sequence surrounding the SNP location were designed. Oligonucleotides specific for the T allele were able to bind nuclear proteins extracted from HepG2 cells, in contrast to the G allele ( Figure 2 ). These data GWAS platforms, it is not surprising why the association of rs2721 with plasma TG levels detected in our analysis was not uncovered by GWAS. However, the complete lack of association evidence for the entire genomic interval, despite repeated linkage evidence, needs to be investigated further. This effect has been reported before, and is not specific to this QTL region or lipid traits (46) .
The lack of comparable findings in other studies may also be due to differences in the recruitment of the study cohorts. In our study design, we excluded individuals with allele T G T G T  G   biotin +  +  +  +  --NE  +  +  --+  + 
